| 15.5 0 (0%) | 02-11 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 18.22  |
1-year : | 18.37 |
| Resists | First : | 15.6 |
Second : | 15.72 |
| Pivot price | 15.5 |
|||
| Supports | First : | 15.39 |
Second : | 12.81 |
| MAs | MA(5) : | 15.49 |
MA(20) : | 15.53 |
| MA(100) : | 12.17 |
MA(250) : | 11.58 |
|
| MACD | MACD : | 0.3 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 17.3 | D(3) : | 16.9 |
| RSI | RSI(14): 75.9 | |||
| 52-week | High : | 15.72 | Low : | 9.19 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ DVAX ] has closed above bottom band by 46.9%. Bollinger Bands are 90.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 18 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 15.54 - 15.61 | 15.61 - 15.67 |
| Low: | 15.28 - 15.39 | 15.39 - 15.48 |
| Close: | 15.35 - 15.51 | 15.51 - 15.64 |
Dynavax Technologies Corporation is a biopharmaceutical firm specializing in the development and market introduction of innovative vaccines, primarily operating in the United States. The company's lead product is HEPLISAV-B, a vaccine approved for adults 18 years and older in the U.S. and Europe, which offers protection against all identified subtypes of the hepatitis B virus. Additionally, Dynavax produces and distributes CpG 1018, the specific adjuvant ingredient used in HEPLISAV-B. Dynavax maintains several strategic alliances, including a collaboration agreement with Valneva Scotland Limited, an agreement with Serum Institute of India Pvt. Ltd., and a sublicense agreement with Merck, Sharp & Dohme Corp. The company, incorporated in 1996, was originally named Double Helix Corporation before adopting the name Dynavax Technologies Corporation in September of that year. Its corporate headquarters are situated in Emeryville, California.
Tue, 10 Feb 2026
Dynavax Technologies Announced Transfer or Voluntary Withdrawal of Listing - TradingView
Tue, 10 Feb 2026
Sanofi completes acquisition of Dynavax Technologies, triggers Nasdaq delisting - Investing.com
Fri, 30 Jan 2026
Dynavax President and COO Sells 114,000 Shares on Sanofi Acquisition News - The Motley Fool
Wed, 14 Jan 2026
Jim Cramer Highlights Sanofi’s Bid for Dynavax - Yahoo Finance
Sat, 10 Jan 2026
Is It Time To Reassess Dynavax Technologies (DVAX) After Its Recent Share Price Surge - Yahoo Finance
Tue, 06 Jan 2026
Dynavax Technologies Corporation (NASDAQ:DVAX) Surges 42% Yet Its Low P/S Is No Reason For Excitement - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 114 (M) |
| Shares Float | 100 (M) |
| Held by Insiders | 0.7 (%) |
| Held by Institutions | 101.5 (%) |
| Shares Short | 9,790 (K) |
| Shares Short P.Month | 10,620 (K) |
| EPS | -0.38 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.55 |
| Profit Margin | -13.2 % |
| Operating Margin | 24.7 % |
| Return on Assets (ttm) | 1.2 % |
| Return on Equity (ttm) | -7.2 % |
| Qtrly Rev. Growth | 17.7 % |
| Gross Profit (p.s.) | 1.79 |
| Sales Per Share | 2.9 |
| EBITDA (p.s.) | 0.21 |
| Qtrly Earnings Growth | 69.3 % |
| Operating Cash Flow | 91 (M) |
| Levered Free Cash Flow | 51 (M) |
| PE Ratio | -41.9 |
| PEG Ratio | 0 |
| Price to Book value | 3.4 |
| Price to Sales | 5.33 |
| Price to Cash Flow | 19.44 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|